Triple Negative and HER-2 Positive Breast Cancer Outcome After Neoadjuvant

Background: Understanding the prevalence and nature of surgical outcomes and complications in TNBC and HER2-Positive breast cancer patients can guide clinicians in optimizing treatment strategies, improving postoperative care and ultimately enhancing the overall quality of care for breast cancer patients. This research aims to evaluate and compare the prevalence of various surgical outcomes and postoperative complications in patients with Triple-Negative Breast Cancer (TNBC) and HER2-Positive Breast Cancer who have undergone Neoadjuvant Therapy (NAT). Materials and Methods: A retrospective cohort study was conducted involving a cohort of TNBC and HER2-positive breast cancer patients who received neoadjuvant therapy followed by surgical intervention. Patient data, including demographics, tumor characteristics, type of neoadjuvant therapy administered, surgical outcomes (e.g., extent of surgery, lymph node involvement) and postoperative complications (e.g., surgical site infections, wound dehiscence, hematoma formation), were collected and analyzed. The prevalence of these outcomes and complications was assessed and compared between those who received NAT and those who didn't receive it. Results: The prevalence of TNBC was 13.1% and HER2-positive breast Cancer was 38.6%. It was observed that re-excision was independently associated with patients who did not undergo neoadjuvant therapy (p<0.05). About 16.6% had Extensive complication rates and flap necrosis was seen in 5.5% of patients. Conclusion: This research provides valuable insights into the surgical management of TNBC and HER2-positive breast cancer patients following neoadjuvant therapy. It is essential to consider a comprehensive evaluation of individual patient cases and consult with healthcare professionals to make informed decisions about treatment strategies for triple-negative breast cancer patients.